Abstracts tagged "Diagnostic Tests"

Abstract Number: 2993 • 2017 ACR/ARHP Annual Meeting
Knee Joint Sounds: A Non-Invasive Modality for Classifying Knee Joint Health in Juvenile Idiopathic Arthritis
Daniel Whittingslow¹, Beren Semiz², Lori Ponder³, Patricia Vega-Fernandez⁴, Omer Inan⁵ and Sampath Prahalad⁶, ¹Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, ²Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, ³Emory University, Atlanta, GA, ⁴Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁵Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, ⁶Pediatrics, Emory Children's Center, Atlanta, GA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common, chronic, childhood rheumatic disease and an important cause of disability. It is characterized by persistent inflammation…
Abstract Number: 172 • 2017 ACR/ARHP Annual Meeting
Optimizing Precision Medicine By Using Genetics to Assign Diagnostic Prior Probabilities to Patients with Synovitis
Rachel Knevel^1,2,3,4, Chikashi Terao^5,6,7, Jing Cui^1,8, Kamil Slowikowski^2,9,10, TWJ Huizinga³, Elizabeth Karlson¹¹ and Soumya Raychaudhuri^1,2,12,13, ¹Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Bosten, MA, ⁵Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, ⁶Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan, ⁷Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁸Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁹Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical Schoo, Boston, MA, ¹⁰Division of Genetics, Brigham and Women's Hospital, Harvard Medical Schoo, Boston, MA, ¹¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹²Department of Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ¹³Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: As the cost of genome-wide genotyping plummets, and biobanking efforts integrating medical records and genetics are rapidly expanding, many patients will have genotyping available…
Abstract Number: 441 • 2017 ACR/ARHP Annual Meeting
Social Media Based, Direct-to-Patient Study Designed for Development of “from Home” Testing for Rheumatoid Arthritis Patients Is Feasible and Engaged Individuals with Distinct Clinical Characteristics
Kristen Warren¹, Olga Derbeneva¹, Francisco Flores¹, Michelle Frits², James Healy¹, Christine Iannaccone³, Omar Khalid¹, Krishna Morampudi¹, Nancy Shadick⁴, Michael Weinblatt⁴, Hemani Wijesuriya¹ and Robert Terbrueggen¹, ¹DxTerity, Rancho Dominguez, CA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Physicians equipped with low cost, patient-administered, “from home” genomic tests for monitoring disease activity and therapy response could revolutionize treatment for rheumatoid arthritis…
Abstract Number: 581 • 2017 ACR/ARHP Annual Meeting
Diagnostic Value of Anti-CD74 Antibodies in Early Axial Spondyloarthritis: Data from the Spondyloarthritis Caught Early (SPACE) Cohort
Janneke de Winter¹, Marleen van de Sande¹, Niklas Thomas Baerlecken², Inger Berg³, Roberta Ramonda⁴, Désirée van der Heijde⁵, Floris van Gaalen⁶, Torsten Witte⁷ and Dominique Baeten^1,8, ¹Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, Private Practice, Cologne, Germany, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ⁸UCB Pharma, Slough, United Kingdom
Background/Purpose: Anti-CD74 IgG antibodies are reported to be elevated in serum of patients with axial spondyloarthritis (axSpA). This study aimed to assess the diagnostic value…
Abstract Number: 695 • 2017 ACR/ARHP Annual Meeting
Development of a Multimarker Model for the Detection of Systemic Lupus Erythematosus Based on New and Traditional Autoantibodies
Petra Budde¹, Hans-Dieter Zucht¹, Johannes Schulte-Pelkum¹, Daniel Wirtz¹, Torsten Witte², Matthias Schneider³ and Peter Schulz-Knappe¹, ¹Protagen AG, Dortmund, Germany, ²Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ³Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany
Background/Purpose: Given the heterogeneity of clinical presentations, the diagnosis of Systemic Lupus Erythematosus (SLE) can be challenging, in particular in those patients presenting with early…
Abstract Number: 56 • 2017 Pediatric Rheumatology Symposium
Prevalence of Serum 14-3-3η in Juvenile Idiopathic Arthritis
Iris Reyhan¹, Olga S. Zhukov², Robert J. Lagier³, Robert Bridgforth⁴, Gary J Williams⁵, Joanna M. Popov², Stanley J. Naides² and Andreas Reiff⁶, ¹Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, ²Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ³Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁴quest diagnostics Nichols Institue, clemente, CA, ⁵Nicolas Institue, Quest Diagnostics, San Juan Capistrano, CA, ⁶Childrens Hospital of Los Angeles, Los Angeles, CA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease. Currently, diagnosis is based on clinical assessment defined by the International League of…
Abstract Number: 71 • 2017 Pediatric Rheumatology Symposium
Consensus-based diagnostic approach to systemic juvenile idiopathic arthritis in Germany
Claas Hinze¹, Dirk Holzinger¹, Elke Lainka², Johannes Peter Haas³, Tilmann Kallinich⁴, Ulrich Neudorf², Helmut Wittkowski¹, Gerd Horneff⁵, Dirk Foell⁶ and PRO-KIND study group on SJIA, ¹Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ²University of Essen, Essen, Germany, ³Center for Pediatric and Adolescent Rheumatology Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany, ⁴Charite, University Medicine Berlin, Berlin, Germany, ⁵Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁶Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is currently classified by the International League of Associations for Rheumatology (ILAR) classification criteria. It is characterized by severe…
Abstract Number: 1334 • 2016 ACR/ARHP Annual Meeting
Contribution of Diagnostic Investigations in the Management of Uveitis: Retrospective Analysis of 300 Patients
Jérôme Hadjadj¹, Thibault Chapron², Manal Assala¹, Sawsen Salah², Bertrand Dunogue¹, Matthieu Groh³, Philippe Blanche¹, Luc Mouthon⁴, Dominique Monnet², Claire Le Jeunne⁴, Antoine Brezin² and Benjamin Terrier³, ¹Internal Medicine, Cochin Hospital, Paris, France, ²Ophtalmology, Cochin Hospital, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁴Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Uveitis represents a diagnostic and therapeutic challenge, as well as an economic one, due to its heterogeneous presentation, multiple underlying causes and lack of…
Abstract Number: 1518 • 2016 ACR/ARHP Annual Meeting
Immunoglobulin Binding Protein (BiP), an Antigen for CCP Sero-Positive Rheumatoid Arthritis Patients, Can Result in a False Positive Quantiferon-Gold Tuberculosis Test
JoAnn Ball¹, Kelsy Greenwald¹, Atul A. Deodhar² and Kevin L. Winthrop³, ¹Rheumatology, Desert Medical Advances, Palm Desert, CA, ²Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ³Oregon Health and Sciences University, Portland, OR
Background/Purpose: Citrullinated BiP is a newly described target for cyclic citrullinated peptide(CCP). BiP in both serum and synovial fluid is over-expressed in RA patients and…
Abstract Number: 1892 • 2016 ACR/ARHP Annual Meeting
Immunosignature Technology Differentiates Patients with Systemic Sclerosis and Internal Organ Involvement
Lorinda Chung¹, David Fiorentino², Robert Gerwien³, Kathleen Jia⁴, Joseph Barten Legutki³, Antonio Valenzuela Vergara⁴, Lisa Zhu⁴, Theodore M. Tarasow³ and Kathryn Sykes³, ¹Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, ³HealthTell, Inc, san ramon, CA, ⁴Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease (CTD) characterized by fibrosis, vascular complications, and inflammation affecting both skin and internal organs. Diagnosis of…
Abstract Number: 1902 • 2016 ACR/ARHP Annual Meeting
Detecting the Pulmonary Vascular Involvement and the Changes in Gene Activation Profiles at Early Stage of Systemic Sclerosis in Patients with Raynaud Phenomenon
Yoshinobu Koyama¹, Soichiro Fuke², Yoshiharu Sato³ and Toshie Higuchi⁴, ¹Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan, ²Department of Cardiology, Japan Red Cross Okayama Hospital, Okayama, Japan, ³DNA Chip Research Inc, Yokohama, Japan, ⁴Center for Autoimmune Diseases, Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan
Background/Purpose: Raynaud phenomenon (RP) is known to precede other disease manifestations of systemic sclerosis (SSc), and classically viewed as reversible vasospasm due to functional changes…
Abstract Number: 1926 • 2016 ACR/ARHP Annual Meeting
Indications for Testing and Diagnostic Outcome in Patients with Positive ANCA at a Canadian Tertiary Care Centre
Cyrus Chehroudi^1,2, Ronald Booth^3,4 and Nataliya Milman^4,5,6, ¹Rheumatology, The Ottawa Hospital, Ottawa, ON, Canada, ²Medicine, University of Ottawa, Ottawa, ON, Canada, ³Division of Biochemistry, The Ottawa Hospital, Ottawa, ON, Canada, ⁴Department of Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁵Department of Medicine, University of Ottawa, Ottawa, ON, Canada, ⁶Division of Rheumatology, The Ottawa Hospital, Ottawa, ON, Canada
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) are a hallmark of a subset of small vasculitides collectively termed ANCA-associated vasculitis (AAV). With widespread availability of ANCA testing,…
Abstract Number: 2007 • 2016 ACR/ARHP Annual Meeting
Sensitivity and Specificity of Autoantibodies Against CD74 in Early Axial Spondyloarthritis
Torsten Witte¹, Elke Riechers², Niklas Thomas Baerlecken³, Xenofon Baraliakos⁴, Katrin Achilles-Mehr Bakhsh⁵, Peer Aries⁶, Bettina Bannert⁷, Klaus Becker⁸, Jan Brandt-Juergens⁹, Juergen Braun¹⁰, Boris P. Ehrenstein¹¹, Hartwig Euler¹², Martin Fleck¹³, Reinhard Hein¹⁴, Kirsten Karberg¹⁵, Lars Koehler¹⁶, Torsten Matthias¹⁷, Regina Max¹⁸, Adelheid Melzer¹⁹, Dirk Meyer-Olson²⁰, Juergen Rech²¹, Karin Rockwitz²², Martin Rudwaleit²³, Eva Schweikhard¹⁷, Joachim Sieper²⁴, Carsten Stille¹⁶, Ulrich von Hinüber²⁵, Peter Wagener²⁶, Heike Weidemann²⁷ and Silke Zinke¹⁵, ¹Clinic for Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ²Medical University Hannover, Hannover, Germany, ³Clinical Immunology and Rheumatology, MD, Hannover, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumatology, Hannover, Hannover, Germany, ⁶Rheumatologie im Struenseehaus, Hamburg, Germany, ⁷Department of Internal Medicine, Clinic for Rheumatology and Clinical Immunology, Freiburg, Germany, ⁸Rheumapraxis Blaubeuren, Blaubeuren, Germany, ⁹Praxis Brandt-Juergens/Karberg, Berlin, Germany, ¹⁰Rheumazentrum Ruhrgebiet, Herne, Germany, ¹¹Department of Rheumatology/Clinical Immunology, Asklepios Medical Center, 93077 Bad Abbach, Germany, ¹²Rheumapraxis Hamburg, Hamburg, Germany, ¹³Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany, ¹⁴Rheumapraxis Nienburg, Nienburg, Germany, ¹⁵Rheumapraxis, Berlin, Germany, ¹⁶Rheumapraxis, Hannover, Germany, ¹⁷Aesku.Diagnostics, Wendelsheim, Germany, ¹⁸Dept. of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ¹⁹Rheumapraxis, Seesen, Germany, ²⁰m&i Fachklinik Bad Pyrmont, Bad Pyrmont, Germany, ²¹Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ²²Rheumatologic Practice, Goslar, Germany, ²³Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany, ²⁴Rheumatology Department, Charité – University Medicine Berlin, Berlin, Germany, ²⁵Rheumapraxis Hildesheim, Hildesheim, Germany, ²⁶Rheumapraxis, Nienburg, Germany, ²⁷Rheumapraxis Hannover, Hannover, Germany
Background/Purpose: Making the diagnosis of axial spondyloarthritis (axSpA) may be difficult. Antibodies against CD74 have been shown to be present in 2/3 of patients…
Abstract Number: 2075 • 2016 ACR/ARHP Annual Meeting
No Detection of Varicella-Zoster Virus in Temporal Arteries of Patients with Giant Cell Arteritis
Francesco Muratore¹, Stefania Croci², Ione Tamagnini³, Alessandro Zerbini², Salvatore Bellafiore⁴, Lucia Belloni⁵, Luigi Boiardi⁶, Alessandra Bisagni⁷, Maria Parmeggiani⁸, Alberto Cavazza⁹ and Carlo Salvarani¹, ¹Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ²Clinical Immunology, Allergy and Advanced Biotechnologies Unit,, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ³Pathology Unit, Department of Oncology, Arsicpedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁴Pathology Unit, Department of Oncology, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁵Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁶Rheumatology Unit, Arcispedale S.Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁷Pathology Unit, Department of Oncology, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁸. Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁹Pathology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy
Background/Purpose: Recent studies found an high prevalence of varicella-zoster virus (VZV) infection in temporal arteries (TAs) from both temporal artery biopsy (TAB)-positive and TAB-negative giant…
Abstract Number: 2800 • 2016 ACR/ARHP Annual Meeting
Cell-Bound Complement Activation Products in Multi-Analyte Assay with Algorithm Aid the Diagnosis of Systemic Lupus Erythematosus
James Mossell¹, John A. Goldman², Derren Barken³ and Roberta Alexander⁴, ¹Tift Regional Medical Center, Tifton, GA, ²Medical Quarters #293, Emory St. Joseph’s Hospital, Atlanta, GA, ³Exagen Diagnostics, Vista, CA, ⁴Research & Development, Exagen Diagnostics, Vista, CA
Background/Purpose: Cell-bound complement activation products (CB-CAPs) are sensitive and specific biomarkers in the differential diagnosis of systemic lupus erythematosus (SLE) and other rheumatic diseases, as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.